drugset / Trial / NCT05769075
A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the safety and tolerability of TY-2136b and to determine the recommended phase 2 dose (RP2D), with dose-escalation stage and dose-expansion stage.
Timeline
- Start
- 2023-04-20
- Primary completion
- 2025-01
- Completion
- 2025-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TY-2136b | Unknown | 40 mg | Oral |
| Subject | TY-2136b | Unknown | 420 mg | Oral |
| Subject | TY-2136b | Unknown | — | — |